Renatus Tactical Acquisition Corp I Class A Ordinary Shares

Complete Genomics Appoints Lauren Selig to Board of Directors

Lauren Selig, a current board member of Renatus Tactical Acquisition Corp. I (RTAC), has been appointed to the board of directors of Complete Genomics. The appointment is contingent upon the closing of Swiss Rockets AG's pending acquisition of Complete Genomics. Selig is an entrepreneur and film producer whose credits include Academy Award-winning films, and she leads an investment fund focused on AI, space, and biotechnology. She also currently serves on the boards of XPRIZE and Pendrell. The transaction to acquire Complete Genomics has received approval from Chinese regulators and Swiss Rockets shareholders but remains subject to CFIUS clearance.

•2mo ago

RTAC: 8-K · leadership change

Renatus Tactical Acquisition Corp I appointed Lauren Selig to its Board of Directors effective July 21, 2026. Ms. Selig was also appointed to the Board’s Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee, bringing over 25 years of experience in entertainment, technology, and venture capital. In connection with her appointment, the company’s sponsor, International SPAC Management Group I LLC, will transfer 50,000 Class B ordinary shares to Ms. Selig as compensation.

SEC 8-K•3mo ago

RTAC: 10-Q · periodic report

Renatus Tactical Acquisition Corp I, a blank check company, has not commenced any operations as of March 31, 2026. The company's primary activities have been organizational and preparatory for its initial public offering (IPO) and the search for a business combination. The company reported a net income of $1,808,560 for the three months ended March 31, 2026, primarily due to investment income earned on the cash held in the Trust Account. The company incurred formation and operating expenses of $282,914 during the same period. As of March 31, 2026, the company has cash of $10,977 and working capital of $236,274. The cash held outside of the Trust Account is not sufficient to allow the company to operate for the next twelve months, raising substantial doubt about its ability to continue as a going concern. The company has 24,150,000 Class A ordinary shares and 7,011,288 Class B ordinary shares issued and outstanding. The Class A ordinary shares are subject to possible redemption at $10.36 per share as of March 31, 2026.

SEC 10-Q•5mo ago